Hospital
Baystate Franklin Medical Center
Baystate Franklin Medical Center was paid $29.11M by Medicaid between Jan 2018 and Dec 2024, across 316 billing codes. Its largest line is 99284, emergency room visit (serious) — 16% of everything it billed.
33Billing provider infoBAYSTATE FRANKLIN MEDICAL CENTER
GREENFIELD, MA 01301
GREENFIELD, MA 01301
33aNPI1508867391assigned 08/03/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$29.11M
24GClaims810,833
24DCodes billed316
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#34 of 66
Median peer was paid$29.11M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 133,145 | $4.41M | |
| 2019 | 128,272 | $3.44M | |
| 2020 | 100,103 | $2.55M | |
| 2021 | 108,962 | $3.27M | |
| 2022 | 118,676 | $4.47M | |
| 2023 | 136,137 | $5.71M | |
| 2024incomplete | 85,538 | $5.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 44,716 | 38,860 | $4.67M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 33,560 | 29,984 | $3.56M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 32,529 | 28,807 | $3.46M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 9.7% | 18,831 | 15,692 | $2.84M |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.4% | 8,723 | 6,767 | $2.15M |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.2% | 714 | 676 | $1.22M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.3% | 1,285 | 1,251 | $671K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 6,198 | 5,868 | $626K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 5,428 | 5,111 | $587K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 11,189 | 4,329 | $552K |
| S9485 | Crisis intervention mental health services, per diem | 1.8% | 1,212 | 861 | $531K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 4,968 | 4,588 | $467K |
304 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 4,372 | $421K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,978 | $262K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,142 | $253K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,814 | $238K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,487 | $237K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,357 | $215K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,405 | $210K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,298 | $207K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,575 | $195K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,216 | $193K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,029 | $174K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,344 | $165K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 41,653 | $165K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,057 | $163K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 978 | $162K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,931 | $161K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,609 | $155K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 908 | $152K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 963 | $150K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,839 | $147K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,342 | $142K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,765 | $142K |
| 76830 | Ultrasound, transvaginal | <1% | 1,483 | $132K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,599 | $119K |
| 93971 | <1% | 788 | $118K | |
| G0378 | Hospital observation service, per hour | <1% | 3,772 | $116K |
| 87631 | <1% | 1,725 | $116K | |
| 97161 | <1% | 2,365 | $113K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,574 | $111K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 683 | $107K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,696 | $107K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,631 | $101K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,088 | $97K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 169 | $78K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 547 | $73K |
| 84484 | <1% | 11,594 | $63K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,372 | $63K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 471 | $63K |
| 84702 | <1% | 6,038 | $62K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 143 | $61K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,404 | $60K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,816 | $47K |
| 83880 | <1% | 3,370 | $47K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,784 | $47K |
| 83605 | <1% | 7,979 | $46K | |
| 97162 | <1% | 983 | $45K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,856 | $45K |
| 83690 | <1% | 10,955 | $41K | |
| ATP14 | <1% | 5,599 | $41K | |
| 12001 | <1% | 274 | $39K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 258 | $36K |
| ATP07 | <1% | 5,236 | $35K | |
| 93975 | <1% | 425 | $29K | |
| 97035 | <1% | 699 | $29K | |
| 71250 | <1% | 654 | $29K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,208 | $28K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,195 | $28K |
| 80053 | Comprehensive metabolic panel | <1% | 12,023 | $27K |
| 87040 | <1% | 4,367 | $27K | |
| ATP08 | <1% | 4,728 | $27K | |
| 81025 | <1% | 5,100 | $27K | |
| 94060 | <1% | 383 | $27K | |
| 76642 | <1% | 303 | $25K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,411 | $25K |
| ATP11 | <1% | 3,400 | $24K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 259 | $24K |
| 83735 | <1% | 6,659 | $22K | |
| 73630 | <1% | 1,618 | $21K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,542 | $21K |
| V5266 | Battery for use in hearing device | <1% | 303 | $20K |
| 86850 | <1% | 3,156 | $20K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,109 | $19K |
| 87088 | <1% | 2,225 | $18K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 54 | $17K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 459 | $16K |
| 70496 | <1% | 186 | $16K | |
| 93017 | <1% | 274 | $16K | |
| 85027 | <1% | 4,893 | $16K | |
| 94727 | <1% | 430 | $16K | |
| 76770 | <1% | 108 | $15K | |
| 85379 | <1% | 2,586 | $14K | |
| 73130 | <1% | 1,023 | $14K | |
| 81001 | <1% | 8,024 | $14K | |
| 92567 | <1% | 505 | $14K | |
| 73030 | <1% | 1,093 | $13K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,093 | $13K |
| 73560 | <1% | 1,285 | $13K | |
| 73610 | <1% | 1,221 | $12K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,564 | $12K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 2,177 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,755 | $11K |
| 86780 | <1% | 1,081 | $11K | |
| 0002A | <1% | 429 | $11K | |
| 0001A | <1% | 459 | $11K | |
| 71271 | <1% | 615 | $11K | |
| 80051 | <1% | 19,588 | $10K | |
| 92557 | <1% | 194 | $10K | |
| 85610 | <1% | 6,074 | $10K | |
| 90715 | <1% | 835 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,089 | $9K |
| 72100 | <1% | 484 | $9K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,580 | $9K |
| 87340 | <1% | 1,093 | $9K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,955 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,219 | $8K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,837 | $8K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,530 | $8K |
| 81015 | <1% | 5,049 | $8K | |
| 87081 | <1% | 1,608 | $8K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 52 | $8K |
| 76801 | <1% | 127 | $7K | |
| 94729 | <1% | 387 | $7K | |
| 59025 | Fetal non-stress test | <1% | 26 | $7K |
| 74018 | <1% | 229 | $7K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 164 | $7K |
| 86140 | <1% | 2,380 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,847 | $7K |
| 73110 | <1% | 467 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 364 | $6K |
| 73502 | <1% | 479 | $6K | |
| 86900 | <1% | 3,142 | $6K | |
| 86901 | <1% | 3,142 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,842 | $6K |
| 82565 | <1% | 20,744 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 420 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 46 | $5K |
| 82947 | <1% | 16,433 | $5K | |
| 87186 | <1% | 1,128 | $5K | |
| 81513 | <1% | 61 | $5K | |
| 86762 | <1% | 368 | $4K | |
| 76942 | <1% | 28 | $4K | |
| 87070 | <1% | 725 | $4K | |
| 90686 | <1% | 837 | $4K | |
| 85730 | <1% | 1,509 | $4K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 203 | $4K |
| 84520 | <1% | 19,891 | $4K | |
| 97012 | <1% | 95 | $4K | |
| 29125 | <1% | 27 | $4K | |
| 84439 | <1% | 868 | $4K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 28 | $4K |
| 82728 | <1% | 544 | $4K | |
| ATP10 | <1% | 641 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,233 | $3K |
| 93970 | <1% | 26 | $3K | |
| 90633 | <1% | 209 | $3K | |
| 86803 | <1% | 340 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 146 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,402 | $3K |
| 85652 | <1% | 2,010 | $3K | |
| ATP17 | <1% | 463 | $3K | |
| ATP15 | <1% | 457 | $3K | |
| ATP06 | <1% | 406 | $2K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 26 | $2K |
| 84460 | <1% | 9,433 | $2K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 102 | $2K |
| 90480 | <1% | 47 | $2K | |
| 73140 | <1% | 94 | $2K | |
| 84450 | <1% | 9,227 | $2K | |
| 94618 | <1% | 16 | $2K | |
| 96415 | <1% | 16 | $2K | |
| 82607 | <1% | 345 | $2K | |
| 83655 | <1% | 163 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,172 | $2K |
| 95806 | <1% | 12 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,814 | $2K |
| ATP09 | <1% | 263 | $2K | |
| 87147 | <1% | 435 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 13 | $2K |
| 93308 | <1% | 13 | $2K | |
| 90651 | <1% | 304 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 39,853 | $2K |
| 12011 | <1% | 12 | $2K | |
| 86618 | <1% | 170 | $2K | |
| 87481 | <1% | 63 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 353 | $2K |
| 87205 | <1% | 555 | $1K | |
| 90677 | <1% | 279 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 44 | $1K |
| J3490 | Unclassified drugs | <1% | 1,067 | $1K |
| 90675 | <1% | 23 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 67 | $1K |
| 82247 | <1% | 7,839 | $1K | |
| 87077 | <1% | 624 | $1K | |
| 84075 | <1% | 7,197 | $1K | |
| 90656 | <1% | 78 | $1K | |
| 81003 | <1% | 1,021 | $1K | |
| 86003 | <1% | 26 | $1K | |
| 82570 | <1% | 429 | $1K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 28 | $1K |
| ATP02 | <1% | 345 | $1K | |
| Q3014 | Telehealth originating site facility fee | <1% | 473 | $963.45 |
| 77065 | Tomosynthesis, mammo | <1% | 42 | $953.74 |
| ATP03 | <1% | 397 | $870.55 | |
| 84153 | <1% | 96 | $815.28 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 890 | $789.78 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,776 | $788.64 |
| 0124A | <1% | 32 | $779.79 | |
| 97803 | <1% | 12 | $765.50 | |
| 83550 | <1% | 137 | $739.83 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,853 | $734.90 |
| 96367 | <1% | 37 | $698.13 | |
| 83540 | <1% | 174 | $693.93 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 40 | $669.18 |
| 51798 | <1% | 484 | $655.82 | |
| 80061 | Lipid panel | <1% | 2,057 | $652.04 |
| 70486 | <1% | 24 | $637.50 | |
| 73562 | <1% | 25 | $630.32 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 778 | $593.11 |
| 76536 | <1% | 13 | $564.80 | |
| 90474 | <1% | 354 | $547.64 | |
| 70498 | <1% | 184 | $537.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 19 | $514.59 |
| 82746 | <1% | 74 | $506.67 | |
| ATP12 | <1% | 73 | $502.20 | |
| 80164 | <1% | 104 | $492.81 | |
| 77080 | <1% | 27 | $464.94 | |
| 73590 | <1% | 26 | $425.81 | |
| 72110 | <1% | 13 | $413.45 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,463 | $400.03 |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 15 | $369.20 |
| 83516 | <1% | 34 | $367.62 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 38 | $325.00 |
| 97597 | <1% | 16 | $281.76 | |
| 86704 | <1% | 39 | $274.75 | |
| 90714 | <1% | 15 | $269.38 | |
| 90670 | <1% | 273 | $253.80 | |
| 73080 | <1% | 17 | $237.09 | |
| 82043 | <1% | 123 | $233.36 | |
| 80076 | <1% | 928 | $229.24 | |
| 87476 | <1% | 15 | $216.65 | |
| 82784 | <1% | 30 | $214.48 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 130 | $202.72 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,832 | $186.07 |
| 82550 | <1% | 940 | $176.16 | |
| 80178 | <1% | 48 | $170.50 | |
| 90674 | <1% | 13 | $163.92 | |
| 85018 | <1% | 86 | $156.75 | |
| 82010 | <1% | 46 | $154.21 | |
| 94664 | <1% | 499 | $149.44 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 85 | $141.47 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 277 | $141.47 |
| 91320 | <1% | 12 | $131.10 | |
| 86038 | <1% | 15 | $124.60 | |
| 86706 | <1% | 14 | $118.69 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 119 | $100.07 |
| ATP16 | <1% | 17 | $98.01 | |
| 96376 | <1% | 4,682 | $93.06 | |
| 90734 | <1% | 51 | $86.82 | |
| 90671 | <1% | 28 | $86.82 | |
| 82950 | <1% | 13 | $63.57 | |
| 86308 | <1% | 13 | $58.74 | |
| 84156 | <1% | 20 | $52.78 | |
| 82800 | <1% | 13 | $48.78 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 74 | $45.73 |
| ATP04 | <1% | 15 | $43.44 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 147 | $42.38 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 162 | $27.02 |
| 82962 | <1% | 5,826 | $25.63 | |
| 84100 | <1% | 976 | $9.19 | |
| 90662 | <1% | 70 | $6.03 | |
| 83615 | <1% | 114 | $5.33 | |
| 82310 | <1% | 94 | $5.33 | |
| 90839 | <1% | 48 | $2.96 | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 24 | $0.01 |
| 90723 | 0% | 367 | $0.00 | |
| 94760 | 0% | 566 | $0.00 | |
| 94644 | 0% | 491 | $0.00 | |
| 90696 | 0% | 12 | $0.00 | |
| 90680 | 0% | 288 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 112 | $0.00 |
| 90697 | 0% | 30 | $0.00 | |
| 82040 | 0% | 224 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 250 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 257 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 57 | $0.00 |
| 70320 | 0% | 15 | $0.00 | |
| 90632 | 0% | 12 | $0.00 | |
| 90716 | 0% | 37 | $0.00 | |
| 88304 | 0% | 12 | $0.00 | |
| 87478 | 0% | 14 | $0.00 | |
| 90619 | 0% | 12 | $0.00 | |
| 87468 | 0% | 14 | $0.00 | |
| 82248 | 0% | 229 | $0.00 | |
| 70310 | 0% | 99 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 315 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 38 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 162 | $0.00 |
| 90710 | 0% | 50 | $0.00 | |
| 90648 | 0% | 537 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 468 | $0.00 |
| 80143 | 0% | 248 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 89 | $0.00 |
| 87469 | 0% | 14 | $0.00 | |
| 80179 | 0% | 161 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 517 | $0.00 |
| 90461 | 0% | 204 | $0.00 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 97 | $0.00 |
| 84155 | 0% | 79 | $0.00 | |
| 91308 | 0% | 18 | $0.00 | |
| 84550 | 0% | 33 | $0.00 | |
| 91300 | 0% | 520 | $0.00 | |
| 90700 | 0% | 29 | $0.00 | |
| 90707 | 0% | 26 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCARTHY, RAYMOND (SR VP, CFO & TREAS, BAYSTATE HEALTH)
| Provider | Location | Paid |
|---|---|---|
| Baystate Medical Center INC | Springfield, MA | $40.55M |
| Baystate Wing Hospital Corporation | Palmer, MA | $38.22M |
| Baystate Wing Hospital Corporation | Palmer, MA | $2.29M |
| Baystate Medical Center INC | Springfield, MA | $1.12M |
| Baystate Franklin Medical Center | Greenfield, MA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.